Phase I study to evaluate the safety, tolerability, and efficacy of VCN-01 in combination with durvalumab (MEDI4736) in subjects with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)

被引：0
|
作者：
Jove, M. [1 ]
Brana, I. [2 ]
Oliva Bernal, M. [3 ]
Hernando-Calvo, A. [4 ]
Erasun Lecuona, C. [5 ]
Assaf Pastrana, J. D. [6 ]
Bazan Peregrino, M. [7 ]
Mato-Berciano, A. [8 ]
Maliandi, M. V. [8 ]
Torres-Manjon, S. [9 ]
Martinez De Villareal, J. [10 ]
Real, F. X. [11 ]
Nuciforo, P. G. [12 ]
Alemany, R. [13 ]
Capella, G. [14 ]
Blasi, E. [15 ]
Blasco, C. [16 ]
Cascallo Piqueras, M. [17 ]
Mesia Nin, R. [18 ]
机构：
[1] Hosp Duran & Reynals, Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[2] Vall dHebron Univ Hosp, Mol Therapeut Res Unit, Barcelona, Spain
[3] Hosp Duran & Reynals, Div Med Oncol, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Barcelona, Spain
[4] Vall dHebron Inst Oncol VHIO, Mol Therapeut Res Unit, Early Drug Dev Unit, La Caixa Res UITM, Barcelona, Spain
[5] Hosp Duran & Reynals, Oncol Dept, ICO Inst Catala Oncol Hosp, Lhospitalet De Llobregat, Spain
[6] Vall dHebron Univ Hosp, Oncol Dept, Barcelona, Spain
[7] VCN Biosci SL, R&D, Barcelona, Spain
[8] VCN Biosci SL, R&D, Sant Cugat Del Valles, Spain
[9] IDIBELL, Catalan Inst Oncol ICO, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Barcelona, Spain
[10] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Madrid, Spain
[11] CNIO Ctr Nacl Invest Oncol, Epithelial Carcinogenesis Grp, Mol Oncol Programme, Madrid, Spain
[12] Vall dHebron Inst Oncol VHIO, Mol Oncol Dept, Cellex Ctr, Barcelona, Spain
[13] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Program Mol Mech & Expt Therapy Oncol Oncobell, Lhospitalet De Llobregat, Spain
[14] Hosp Duran & Reynals, ICO Inst Catala Oncol Hosp, Hereditary Canc Program, Lhospitalet De Llobregat, Spain
[15] VCN Biosci SL, Regulatory, Sant Cugat Del Valles, Spain
[16] VCN Biosci SL, Clin Operat, Barcelona, Spain
[17] VCN Biosci SL, Clin Res, Barcelona, Spain
[18] Hosp Duran & Reynals, ICO Inst Catala Oncol, Dept Med Oncol, Lhospitalet De Llobregat, Spain
来源：
ANNALS OF ONCOLOGY | 2022年 / 33卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1231P
引用
收藏
页码：S1112 / S1112
页数：1
相关论文
共 50 条
  • [31] A phase I study of avelumab, palbociclib, and cetuximab (APC) in recurrent or metastatic head and neck squamous cell carcinoma (RM HNSCC).
    Gold, Kathryn A.
    Sacco, Assuntina
    Bykowski, Julie
    Daniels, Gregory
    Pittman, Emily
    Messer, Karen
    Chen, Ruifeng
    Cohen, Ezra
    CANCER RESEARCH, 2021, 81 (13)
  • [32] A phase I study of everolimus in combination with cetuximab and cisplatin as first-line therapy inrecurrent and metastatic (R/M) head and neck squamous cell carcinoma (HNSCC)
    Chung, Christine H.
    Wang, Hao
    Tsottles, Nancy
    Gourin, Christine Gail
    Agrawal, Nishant
    Molinolo, Alfredo
    Gutkind, Silvio
    Forastiere, Arlene A.
    Marur, Shanthi
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [33] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Fury, Matthew G.
    Sherman, Eric
    Ho, Alan
    Katabi, Nora
    Sima, Camelia
    Kelly, Katherine W.
    Nwankwo, Oby
    Haque, Sofia
    Pfister, David G.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (01) : 121 - 128
  • [34] A phase I study of temsirolimus plus carboplatin plus paclitaxel for patients with recurrent or metastatic (R/M) head and neck squamous cell cancer (HNSCC)
    Matthew G. Fury
    Eric Sherman
    Alan Ho
    Nora Katabi
    Camelia Sima
    Katherine W. Kelly
    Oby Nwankwo
    Sofia Haque
    David G. Pfister
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 121 - 128
  • [35] A phase II study evaluating tipifarnib in mHRAS, recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) (AIM-HN study)
    Ho, A. L.
    Adkins, D. R.
    Hanna, G. J.
    Bruce, J.
    Ahn, M. J.
    Docampo, L. Iglesias
    Kang, H.
    Wong, D. J.
    Psyrri, A.
    Gillison, M.
    Brana, I.
    Liu, Y. C.
    Hsieh, C. Y.
    Hong, M. H.
    Zhang, Z.
    Balsara, B.
    Saunders, A.
    Hernandez, A. Gasco
    Dale, S.
    Haddad, R.
    ANNALS OF ONCOLOGY, 2023, 34 : S1286 - S1287
  • [36] POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
    Forster, M. D.
    Mason, J.
    Moleron, R.
    Sacco, J. J.
    Beasley, M.
    Ferreira, M. Reis
    Srinivasan, D.
    Yip, K.
    Stewart, G.
    Chiu, K.
    Ward, A.
    Metcalf, R.
    Adedoyin, T.
    Begum, R.
    Chiwewe, M.
    Poole, K.
    Spanswick, V.
    Pathak, Y.
    Counsell, N.
    Rashid, M. K.
    ANNALS OF ONCOLOGY, 2024, 35 : S623 - S624
  • [37] Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).
    Chung, Christine H.
    Saba, Nabil F.
    Steuer, Conor Ernst
    Li, Jiannong
    Bhateja, Priyanka
    Johnson, Matthew
    Masannat, Jude
    Poole, Maria
    Hoening, Dirk
    Song, Feifei
    Hernandez-Prera, Juan C.
    Molina, Helen
    Wenig, Bruce
    Farinhas, Joaquim
    Kish, Julie Ann
    Muzaffar, Jameel
    Kirtane, Kedar
    Rocco, James William
    Schell, Michael J.
    Bonomi, Marcelo Raul
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] A phase I/Il Study of erlotinib (Tarceva) in combination with cisplatin in patients with recurrent or metastatic squamous cell cancer of the head and neck (HNSCC).
    Siu, LL
    Chen, X
    Tsao, M
    Dancey, J
    Pond, GR
    Klein, M
    Winquist, E
    CLINICAL CANCER RESEARCH, 2003, 9 (16) : 6091S - 6091S
  • [39] Safety and efficacy of toripalimab combined with cetuximab in PD-L1 positive untreated recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC): A phase Ib/II study
    Guo, Y.
    Li, D. Z.
    Lin, J.
    Sun, C.
    Cao, G.
    Wu, J.
    Ge, M.
    Hu, D.
    Qu, S.
    Shen, L.
    Wei, Y.
    Zong, J.
    Fang, M.
    Jin, C.
    Li, Z-M.
    Sun, Y.
    Wang, X.
    Zhang, H.
    Wang, W.
    Zhu, Y.
    ANNALS OF ONCOLOGY, 2024, 35 : S625 - S625
  • [40] A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
    Ji, D.
    Sang, Y.
    Liu, X.
    Guo, Y.
    Yang, Y.
    Chen, G.
    Dong, S.
    Wang, Y.
    He, X.
    Ying, H.
    Lu, X.
    Wang, Y.
    Hu, C.
    Ji, Q.
    ANNALS OF ONCOLOGY, 2024, 35 : S626 - S626
12345